Source:http://linkedlifedata.com/resource/pubmed/id/17096329
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2006-12-5
|
pubmed:abstractText |
Insulin-like growth factor binding protein-3 (IGFBP-3) is postulated to be a mediator of growth suppression signals. Here, we examined the methylation status of IGFBP-3 to correlate to clinicopathological factors in human cancers. The methylation status of IGFBP-3 was determined by bisulfite DNA sequencing and was correlated with expression semi-quantified by real-time RT-PCR to develop a methylation-specific PCR (MSP) assay for IGFBP-3. Using the MSP assay, we examined the methylation status of IGFBP-3 in gastric cancer (GC), colorectal cancer (CRC), breast cancer (BC) and malignant mesothelioma (MM). IGFBP-3 methylation was detected in 6 of 13 (46%) and 16 of 24 (67%) GC cell lines and tumors, respectively; 4 of 8 (50%) and 15 of 26 (58%) CRC cell lines and tumors, respectively; 3 of 11 (27%) and 7 of 39 (18%) BC cell lines and tumors, respectively and 1 of 5 (20%) and 18 of 56 (32%) MM cell lines and tumors, respectively. Interestingly, the methylation status of MM specimens from Japanese patients (75%, 12 out of 16 patients) was significantly higher than those from the USA (15%, 6 out of 40 patients) (p < 0.0001), suggesting the presence of ethnic differences in the IGFBP-3 methylation status. We also found that IGFBP-3 methylation was preferentially present in GCs arising in the lower-third of the stomach (p = 0.079). In summary, our results showed that IGFBP-3 methylation played an important role in the silencing of its expression, suggesting that IGFBP-3 may act as a tumor suppressor gene in several human cancers examined.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0020-7136
|
pubmed:author |
pubmed-author:AsanoHiroakiH,
pubmed-author:DateHiroshiH,
pubmed-author:DoiharaHiroyoshiH,
pubmed-author:DoteHideakiH,
pubmed-author:HanafusaTadashiT,
pubmed-author:KatayamaHidekiH,
pubmed-author:KisimotoTakumiT,
pubmed-author:NaitouMinoruM,
pubmed-author:PassHarvery IHI,
pubmed-author:ShimizuNobuyoshiN,
pubmed-author:TomiiKunitoshiK,
pubmed-author:ToyookaShinichiS,
pubmed-author:TsukudaKazunoriK
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
120
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
566-73
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:17096329-5' Flanking Region,
pubmed-meshheading:17096329-Cell Line, Tumor,
pubmed-meshheading:17096329-Colorectal Neoplasms,
pubmed-meshheading:17096329-CpG Islands,
pubmed-meshheading:17096329-DNA, Neoplasm,
pubmed-meshheading:17096329-DNA Methylation,
pubmed-meshheading:17096329-DNA Primers,
pubmed-meshheading:17096329-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:17096329-HT29 Cells,
pubmed-meshheading:17096329-Humans,
pubmed-meshheading:17096329-Insulin-Like Growth Factor Binding Protein 3,
pubmed-meshheading:17096329-Neoplasms,
pubmed-meshheading:17096329-Promoter Regions, Genetic,
pubmed-meshheading:17096329-RNA, Messenger,
pubmed-meshheading:17096329-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:17096329-Sequence Analysis, DNA,
pubmed-meshheading:17096329-Stomach Neoplasms
|
pubmed:year |
2007
|
pubmed:articleTitle |
Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers.
|
pubmed:affiliation |
Department of Cancer and Thoracic Surgery, Shikata Laboratory, Advanced Science Research Center, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|